PRELIMINARY SCIENTIFIC PROGRAM

Thursday, June 13, 2024

8:00 AM - 8:30 AM    Welcome coffee

8:30 AM - 8:40 AM    Introduction on behalf of the scientific committee by Alexandre Mebazaa (Paris, FRA)

Session 1: Cardiogenic Shock: Time for paradigm shift!

Moderated by Christopher O'Connor (Falls Church, USA) and Hannah Schaubroeck (Brussels, BEL)

8:40 AM - 8:50 AM    CS trials: a new approach is needed Susanna Price (London, GBR)
8:50 AM - 9:00 AM    Lessons from ECLS-Shock Holger Thiele (Leipzig, GER)
9:00 AM - 9:10 AM    Further lessons from DAN-GER Jacob Møller (Odense, DEN)
9:10 AM - 9:20 AM      Lessons from observational studies Pascal Leprince (Paris, FRA)
9:20 AM - 9:30 AM  Dealing with heteregoneity in care Erin Bohula (Boston, USA)
9:30 AM - 9:40 AM  Global networking is key Navin Kapur (Boston, USA)
9:40 AM - 9:50 AM  Toward personalized management! Vanessa Blumer (Cleveland, USA)
9:50 AM - 10:30 AM  Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

10:30 AM - 11:00 AM   Coffee break

Session 2: Cardiogenic Shock: Inflammation: a driver of outcome

Moderated by Janine Pöss (Leipzig, GER) & TBD

11:00 AM - 11:10 AM Inflammation markers and Cardiogenic Shock phenotypes Sabri Soussi (Toronto, CAN)
11:10 AM - 11:20 AM Genotyping Alastair Proudfoot (London, GBR)
11:20 AM - 11:25 AM New biomarkers (IL6 and DPP3) Florian Wenzl (Zürich, SUI)
11:25 AM - 11:30 AM Inhibition of DPP3 & inflammation Ferie Azibani (Paris, FRA)
11:30 AM - 11:35 AM DOBERMANN trial Helle Søholm (Copenhagen, DEN)
11:35 AM - 12:00 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

12:00 PM - 1:00 PM Lunch break

Session 3: Improve CS trial design to prevent neutral trial

Moderated by William O'Neill (Detroit, USA) and Susanna Price (London, GBR)

1:00 PM - 1:10 PM We need positive trials Rhonda Monroe (Charlotte, USA)
1:10 PM - 1:20 PM Randomization by patient is not appropriate Alexandre Mebazaa (Paris, FRA)
1:20 PM - 1:30 PM Is clustering by center the answer? Wesley Self (Nashville, USA)
1:30 PM - 1:40 PM Control arm should remain "control" Rebecca Mathew (Ottawa, CAN)
1:40 PM - 1:50 PM SOC in a device trial: a challenge Navin Kapur (Boston, USA)
1:50 PM - 2:00 PM Should we include cardiac arrest ? Uwe Zeymer (Ludwigshafen, GER)
2:00 PM - 2:10 PM Registry-based randomised trials David Morrow (Boston, USA)
2:10 PM - 2:20 PM Education before starting a trial is key Jan Belohlavek (Prague, CZE)
2:20 PM - 2:30 PM eCPR Roberto Lorusso (Maastricht, NED)
2:30 PM - 2:40 PM Win Ratio in critical care: are we ready? Harriette Van Spall (Hamilton, CAN)
2:40 PM - 3:30 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

3:30 PM - 4:00 PM Coffee break

Session 4: Ongoing studies

Moderated by Alessandro Sionis (Barcelona, ESP) and Anu Lala (New York, USA)

4:00 PM - 4:05 PM DOREMI2 Benjamin Hibbert (Ottawa, CAN)
4:05 PM - 4:10 PM RECOVER IV William O'Neill (Detroit, USA)
4:10 PM - 4:15 PM Unload VA-ECMO + Impella Dirk Westermann (Freiburg, GER)
4:15 PM - 4:20 PM Altshock-2 Nuccia Morici (Milan, ITA)
4:20 PM - 4:25 PM ANCHOR Alain Combes (Paris, FRA)
4:25 PM - 4:30 PM LEVO-ECMO Bruno Levy (Nancy, FRA)
4:30 PM - 4:35 PM ISO-SHOCK Mir Babar Basir (Detroit, USA)
4:35 PM - 4:40 PM PACCS Navin Kapur (Boston, USA)
4:40 PM - 4:45 PM IV-cangrelor STEMI shock Sarah Gorgis (Cleveland, USA)
4:45 PM - 5:10 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…
5:10 - 5:30 PM Coffee break

Session 5: Positive trials in critical care: the key role of regulators

Moderated by Mona Fiuzat (Falls Church, USA), Alexandre Mebazaa (Paris, FRA) and Rhonda Monroe (Charlotte, USA)

5:30 PM - 5:35 PM Patient's perspective Rhonda Monroe (Charlotte, USA)
5:35 PM - 5:40 PM Investigator perspective: EU Thomas Lüscher (Zurich, SUI)
5:40 PM - 5:45 PM Investigator perspective: EU Piotr Szymański (ESC, POL)
5:45 PM - 5:50 PM Investigator perspective: US Mitchell Krucoff (Durham, USA)
5:50 PM - 5:55 PM Investigator perspective: Japan Naoki Sato (Tokyo, JPN)
5:55 PM - 6:15 PM Industry perspective: Chuck Simonton (Abiomed, USA); Andres Beiras (Getinge, USA); Karine Bourgeois (4TEEN4, USA), Dominic Allocco (Boston Scientific, USA), Steve Simonson (Windtree Therapeutics) & TBD (Zoll TherOx)
6:15 PM - 6:30 PM Regulators' perspective: FDA Ileana Piña (Cleveland, USA); Bram Zuckerman (FDA, USA) & Norman Stockbridge (FDA, USA)
6:30 PM - 6:40 PM Regulators' perspective: Alan Fraser (EMA, USA) & Maciej Kostrubiec (EMA, USA)
6:40 PM - 6:45 PM Regulators' perspective: Shuichi Mochizuki (PMDA, JPN)
6:45 PM - 6:50 PM NIH perspective George Sopko (NHLBI, USA)
6:50 PM - 7:15 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

7:15 - 7:30 Take home messages Susanna Price (London, UK) and Alexandre Mebazaa (Paris, FRA)

7:30 PM Adjourn & dinner

Friday, June 14, 2024

8:00 AM - 8:30 AM Welcome coffee

8:30 AM - 8:40 AM    Introduction on behalf of the scientific committee by Alexandre Mebazaa (Paris, FRA)

Session 6: Transition from ICU to home: a vulnerable phase

Moderated by TBD

8:40 AM - 8:50 AM    What RCTs are needed to improve outcome after critical illness Margaret Herridge (Toronto, CAN)
8:50 AM - 9:00 AM    START-or-NOT Etienne Gayat (Paris, FRA)
9:00 AM - 9:10 AM    DAPA-ICU François Dépret (Paris, FRA)
9:10 AM - 9:20 AM      Cost of readmission
9:20 AM - 9:55 AM  Industry perspective Lea Ricci (Roche, SUI), Gillian Murtagh (Abbott, USA), TBD (AstraZeneca), , Darshak Sanghavi (Babylon, USA), Danielle Bergman (Bergman, USA) & Shan Jegatheeswaran (JnJ, USA)
9:55 AM - 10:40 AM  Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

10:30 AM - 11:00 AM   Coffee break

Session 7: Acute Heart Failure

Moderated by TBD

11:00 AM - 11:10 AM Primary objectives in implementation RCTs Harriette Van Spall (Hamilton, CAN)
11:10 AM - 11:20 AM STRONG-HF Gad Cotter Momentum (Research, USA)
11:20 AM - 11:30 AM The benefit of combining devices and oral medications Ileana Piña (Cleveland, USA)
11:30 AM - 11:40 AM Which trials are still needed in Acute Heart Failure? Mona Fiuzat (Falls Church, USA)
11:40 AM - 11:50 AM Role of nurses and APPs in implementing therapies Carolyn Rosner (Falls Church, USA)
11:50 AM - 11:55 PM Worsening Heart Failure: how to improve implementation of heart therapies? Annette Kent (FIRE1, USA)
11:55 AM - 12:15 PM Industry perspective Hela Ben Hamouda (Medtronic, FRA), Harjeet Caberwal Boehringer (Ingleheim, USA), Like Jiang (AstraZeneca, USA) & Carlos Eid (Novartis, UAE)
12:15 PM - 12:20 PM Patient's perspective Rhonda Monroe (Charlotte, USA)
12:20 PM - 1:00 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

1:00 PM - 2:00 PM Lunch break

Session 8: How can AI help improve outcomes in the critically ill?

Moderated by Michael Harhay (Philadelphia, USA) and Etienne Gayat (Paris, FRA)

2:00 PM - 2:10 PM Keynote lecture: AI-based algorithms used in critical care Suchi Saria (Baltimore, USA)
2:10 PM - 2:20 PM How AI will transfer clinical trials Bradley Maron (New Haven, USA)
2:20 PM - 2:30 PM How can AI help implementing guidelines? Thomas Lüscher (Zurich, SUI)
2:30 PM - 2:40 PM How can AI help research in my company? Martin Cowie (AstraZeneca, USA)
2:40 PM - 2:50 PM How AI can help in publication and writing grants TBD
2:50 PM - 3:00 PM How can AI help in daily practice? Nico Bruining (Randstad? NLD)
3:00 PM - 3:10 PM TBD Christine Gouillard (Us2.ai, USA)
3:10 PM - 3:15 PM Editor's perspective Romain Pirracchio (JAMA, USA)
3:15 PM - 3:40 PM Industry perspective Anis Ghorbel Precisia (Care, SUI), Mark-Holger Konrad (Philips, USA), Amy Abernethy (Verily, USA), Danielle Bergman (JvionAI, USA) & Shan Jegatheeswaran (JnJ, USA)
3:40 PM - 4:00 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

4:00 PM - 4:15 PM Coffee break

Session 9: Management in massive bleeding

Moderated by Sean Collins (Nashville, USA) and Wesley Self (Nashville, USA)

4:15 PM - 4:25 PM Current global recommendations Natalie Kreitzer (Cincinatti, USA)
4:25 PM - 4:35 PM Prime-time for pragmatic studies in the ED? Alexander Cohen (London, GBR)
4:35 PM - 4:45 PM How to generate evidence to manage surgical hemorrhagic shock Paula Ferrada (Falls Church, USA)
4:45 PM - 5:00 PM Industry perspective Martin Cowie (AstraZeneca, USA) & Maria Borentain (Bayer, USA)
5:05 PM - 5:30 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

5:30 PM Adjourn

5:30 PM - 7:00 PM Dinner in the Embassy of France, Washington D.C.

Saturday, June 15, 2024

8:00 AM - 8:30 AM Welcome coffee

8:30 AM - 8:35 AM Welcome introduction by Alexandre Mebazaa (Paris, FRA)

Session 10: Sepsis: Biomarker-guided therapy

Moderated by TBD

8:35 AM - 8:45 AM Is biomarker-guided therapy ready for prime-time? Bruno François (Limoges, FRA)
8:45 AM - 8:55 AM BOOST Pierre-François Laterre (Brussels, BEL)
8:55 AM - 9:05 AM Septic shock: i-Micro Matthieu Legrand (San Francisco, USA)
9:05 AM - 9:25 AM Industry perspective Steffan Witte (Adrenomed, GER), Margarita Salcedo (Inotrem, FRA), Jean-François Llitjos (bioMérieux, FRA) & Yinong Zhou (Novartis, USA)
9:25 AM - 9:30 AM Regulator's perspective: EMA
9:30 AM - 9:35 AM Regulator's perspective: FDA
9:35 AM - 10:00 AM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

Session 11: Trialists and regulators: can we agree on an endpoint?

Moderated by Nathan Nielsen (Albuquerque, USA) & TBD

10:00 AM - 10:10 AM Mortality is dead Ashish Khanna (Winston-Salem, USA)
10:10 AM - 10:20 AM Change in sofa score TBD
10:20 AM - 10:30 AM Improvement in organ perfusion François Dépret (Paris, FRA)
10:30 AM - 10:40 AM Organ dysfunction Jean-Jacques Garaud (Inotrem, FRA)
10:45 AM - 10:50 AM Patient's perspective Eileen Rubin (Chicago, USA)
10:50AM - 11:00 AM Industry perspective Sai Lyer (SeaStarMed, USA), & Axel Vater (Aptarion Biotech, GER)
11:00 AM - 11:05 AM Regulator's perspective: EMA
11:05 AM - 11:10 AM Regulator's perspective: FDA
11:10 AM - 11:15 AM Regulator's perspective: PDMA
11:15 AM - 11:40 AM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

11:40 AM - 11:30 AM Coffee break

Session 12: Lessons from international ARDS guidelines

12:00 PM - 12:10 PM New global definition of ARDS Michael Matthay (San Francisco, FRA)
12:10 PM - 12:20 PM Impact of the global definition on future trial design Katherine Wick (San Francisco, USA)
12:20 PM - 12:30 PM What are the priorities for future clinical trialists Maurizio Cecconi (Milan, ITA)
12:30 PM - 12:40 PM Ongoing trials with ECMO Alain Combes (Paris, FRA)
12:40 PM - 12:50 PM Lung Division’s support mechanisms for ARDS trials and research Gus Matute-Bello (NIH, USA)
12:50 PM - 12:55 PM Patient perspective Eileen Rubin (Chicago, USA)
12:55PM - 1:05 PM Industry perspective Niels Riedemann (InflaRx, GER) & Negin Hajizadeh (Bayer, USA)
1:05 PM - 1:30 PM Panel discussion with patients, FDA, EMA, PMDA, NIH/NHLBI, industry and more…

1:00 PM Adjourn

Please note: the program above is only indicative and is not yet confirmed. Speakers may be changed according to their availability.

For past editions’ scientific programs, click on the links below: